Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer
2018年6月27日 - 8:05PM
Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a developer of innovative
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases with an initial focus on the development
of RP-G28, a drug candidate with the potential to be the first
FDA-approved treatment for lactose intolerance (LI), today
announced that Andrew J. Ritter has been appointed to the position
of CEO, effective June 27, 2018, succeeding Michael D. Step, who
will remain on the Company’s board of directors and serve as a
consultant to the company.
“As the Company moves forward with the development of RP-G28 by
initiating the “Liberatus” study, the first pivotal Phase 3 trial
of this important new potential therapy, I am confident that as
CEO, Andrew Ritter will continue to guide the Company towards the
successful execution and completion of this program,” said
departing CEO, Michael D. Step.
Andrew Ritter co-founded Ritter Pharmaceuticals in 2007 as a
result of his own personal affliction with lactose intolerance. Mr.
Ritter directed a team of clinical, manufacturing, and regulatory
professionals to develop the Company’s lead product candidate,
RP-G28 and, since 2014, he has served as the Company’s President.
In this role, he developed the scientific foundation for the
Company and recruited a Medical Board comprised of world-class
lactose intolerance and gastrointestinal disease experts. He played
a major role in the Company’s successful Initial Public Offering
(IPO) in 2015 and has led the team in additional, successful
financing rounds both before and subsequent to the IPO. Mr. Ritter
holds an MBA with an emphasis in Finance from The Wharton School,
University of Pennsylvania.
Over the past year, Ritter Pharmaceuticals has been diligently
building its executive team as it prepares for late stage clinical
development of RPG-28. The appointment of Mr. Ritter as CEO comes
on the heels of recent key hires, including John Beck, former CFO
of Ardea Biosciences as chief financial officer and Diane Plotkin,
Ph.D. as vice president of clinical development. Dr. Plotkin brings
extensive late-stage clinical development expertise to the team as
a result of her prior experiences in similar roles at Merck and
ActivX.
“Our goal is to make Ritter Pharmaceuticals a leader in
gastrointestinal disease treatments. With Andrew Ritter’s planned
succession to the role of CEO and these key additions in place, the
management team is well positioned to ensure a smooth transition of
RP-G28 into Phase 3 development and to create continued shareholder
value,” added Ira E. Ritter, co-founder and executive chairman.
Finally, I would like to thank Mike Step for his service as the
Company’s CEO and we are pleased that he will remain on our
Company’s board of directors and continue to work closely with us
to help us execute our strategy as a consultant.”
About Ritter PharmaceuticalsRitter
Pharmaceuticals, Inc. (www.RitterPharma.com, @RitterPharma)
develops novel therapeutic products that modulate the gut
microbiome to treat gastrointestinal diseases. The Company’s lead
product candidate, RP-G28, has the potential to become the first
FDA-approved treatment for lactose intolerance, a condition that
affects millions of people worldwide. RP-G28 has been studied in
Phase 2 trials and entered Phase 3 clinical development in the
second quarter of 2018. The Company is further exploring the
therapeutic potential that gut microbiome changes may have on
treating/preventing a variety of diseases including:
gastrointestinal diseases, cancer, metabolic, and liver
disease.
Forward-Looking StatementsThis press release
may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 that express the
current beliefs and expectations of Ritter Pharmaceuticals’
management, including statements regarding the management
transition and the timing and commencement of our first Phase 3
clinical trial. Any statements contained herein that do not
describe historical facts are forward-looking statements that are
subject to risks and uncertainties that could cause actual results,
performance and achievements to differ materially from those
discussed in such forward-looking statements. Factors that could
affect our actual results are included in the periodic reports on
Form 10-K and Form 10-Q that we file with the Securities and
Exchange Commission. These forward-looking statements are made only
as of the date hereof, and the Company undertakes no obligation to
update or revise the forward-looking statements, except as
otherwise required by law, whether as a result of new information,
future events or otherwise.
Contacts
Investor Contact:
John Beck
310-203-1000
john@ritterpharma.com
Media Contact:
Jules Abraham
CoreIR
917-885-7378
julesa@coreir.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024